DiaSorin (OTCMKTS:DSRLF) Stock Price Down 1.7% – Here’s Why

DiaSorin S.p.A. (OTCMKTS:DSRLF) shares traded down 1.7% on Friday. The stock traded as low as $84.00 and last traded at $84.00. 5 shares were traded during mid-day trading, The stock had previously closed at $85.47.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on DSRLF shares. BNP Paribas Exane cut shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research report on Tuesday, July 7th. Piper Sandler began coverage on DiaSorin in a research report on Thursday, June 11th. They issued a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of DiaSorin in a research note on Tuesday, August 4th. Zacks Research lowered DiaSorin from a “hold” rating to a “strong sell” rating in a report on Thursday, August 6th. Finally, UBS Group cut DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday, August 12th. One equities research analyst has rated the stock with a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Strong Sell”.

DiaSorin Trading Down 1.7%

The business’s fifty day moving average price is $84.89 and its 200-day moving average price is $77.57.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italian healthcare company that develops, manufactures and markets in vitro diagnostic products. Its portfolio is focused on immunodiagnostics and molecular diagnostics used to support the detection and monitoring of diseases and medical conditions.

The company offers diagnostic assays, reagents and analytical systems for areas including infectious diseases, endocrinology, oncology, autoimmune disorders, bone and mineral metabolism, cardiovascular conditions and gastrointestinal diseases.